Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema

• Status: Completed
• Trial end date: 2018-12-28
• Target enrollment: 0
• Participant gender: All

Summary

prospective study evaluating the impact of subthreshold micropulsed laser on the number of Aflibercept injections when used as an adjuvant therapy in eyes with diabetic macular edema.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Al Hadi Hospital
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• older than 18 years old

• diagnosed with DME with central macular thickness (CMT) more than 250 µm measured by OCT

• best corrected visual acuity (BCVA) between 20/400 and 20/40.

Exclusion Criteria:

• patients with intra-ocular surgery as cataract surgery within 6 months

• prior intravitreal injection of any drug within the preceding 6 months

• panretinal photocoagulation (PRP) within the former 4 months.

• Patients with previous macular laser

• patients with vitreo-macular traction (VMT) syndrome

• severe glaucoma

• other retinal vascular diseases

• conditions that impede the OCT interpretation